Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

DISEASE CHARACTERISTICS: Diagnosis of 1 of the following: Recurrent ovarian, fallopian tube, or peritoneal cavity cancer Metastatic breast cancer Advanced endometrial cancer Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m^2 Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Sex Not specified Menopausal status: Not specified Performance status Karnofsky 60-100% Life expectancy Not specified Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic AST and ALT ≤ 2 times upper limit of normal (ULN) Alkaline phosphatase ≤ 2 times ULN Bilirubin normal Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram No history of cardiac disease No New York Heart Association class II-IV heart disease No clinical evidence of congestive heart failure Other Not pregnant or nursing Fertile patients must use effective contraception during and for 3 months after completion of study treatment No active infection requiring antibiotics No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy At least 3 weeks since prior biologic or immunologic agents for this cancer Chemotherapy Recovered from prior chemotherapy Alopecia or neuropathy allowed No prior doxorubicin HCl liposome Other concurrent chemotherapy allowed provided palmar-plantar erythrodysesthesia is not one of the side effects of the therapy No concurrent cytarabine, fluorouracil, liposomal daunorubicin, or capecitabine No concurrent pre-medication with corticosteroids as part of the chemotherapy regimen Endocrine therapy See Chemotherapy At least 3 weeks since prior and no concurrent oral or topical corticosteroids At least 1 week since prior hormonal therapy for this cancer Concurrent hormone replacement therapy allowed Radiotherapy At least 3 weeks since prior radiotherapy for this cancer and recovered Surgery Recovered from prior surgery Other At least 3 weeks since prior and no other concurrent forms of pyridoxine except what is included in a multivitamin No prior anticancer treatment that contraindicates study treatment No concurrent amifostine or other protective agents